eGenesis fetches $125m Series C

eGenesis, a gene-editing and genome-engineering company, has closed $125 million in Series C financing.

eGenesis, a gene-editing and genome-engineering company, has closed $125 million in Series C financing. The backers include Farallon Capital Management, Polaris Partners, HBM Healthcare Investments, Invus, Samsara BioCapital, LifeSci Venture Partners, Irving Investors, Catalio Capital Management, SymBiosis, Altium Capital, Monashee Investment Management, and Osage University Partners.

Source: Press Release